Obesity, high-molecular-weight (HMW) adiponectin, and metabolic risk factors: prevalence and gender-specific associations in Estonia - PubMed (original) (raw)

Obesity, high-molecular-weight (HMW) adiponectin, and metabolic risk factors: prevalence and gender-specific associations in Estonia

Triin Eglit et al. PLoS One. 2013.

Abstract

Background: The metabolic consequences of obesity are associated with an imbalance of adipocytokines, e.g. adiponectin. However, some obese subjects remain metabolically healthy and have adiponectin levels similar to normal body weight subjects. Current estimates of the prevalence of obesity in Estonia have relied only on self-report data.

Objectives: To estimate the prevalence of obesity in Estonia, to test for associations between HMW adiponectin and metabolic risk factors and to test if HMW adiponectin levels differentiate metabolically healthy and metabolically unhealthy subjects.

Methods: We conducted a population-based cross-sectional multicentre study to gather history, examination and blood test results for 495 subjects aged 20-74. Metabolically healthy subjects were free from hypertension, dyslipidaemia, impaired glucose regulation and insulin resistance. Metabolically unhealthy subjects had at least one of these four metabolic abnormalities.

Results: The prevalence of obesity was 29% in men and 34% in women. HMW adiponectin was positively correlated with HDL cholesterol and negatively correlated with triglycerides, obesity, insulin resistance and blood glucose. This effect was driven by metabolically unhealthy subjects in men, but by both metabolically healthy and metabolically unhealthy subjects in women. Metabolically healthy women had higher HMW adiponectin levels than metabolically unhealthy women. 12% of all obese subjects were metabolically healthy, and their HMW adiponectin levels were similar to normal weight subjects.

Conclusions: Obesity is more prevalent in Estonian adults than previously thought. HMW adiponectin levels were associated with various metabolic risk factors in metabolically healthy women but not in metabolically healthy men. For both genders, HMW adiponectin differentiates metabolically healthy obese subjects from metabolically unhealthy obese subjects.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

1. Tsigos C, Hainer V, Basdevant A, Finer N, Fried M, et al. (2008) Management of obesity in adults: European clinical practice guidelines. Obes Facts 1: 106–116. - PMC - PubMed
1. Kopelman P (2007) Health risks accociated with overweight and obesity. Obesity reviews 8: 13–17. - PubMed
1. Hajer GR, van Haeften TW, Visseren FL (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29: 2959–2971. - PubMed
1. Aprahamian TR, Sam F (2011) Adiponectin in cardiovascular inflammation and obesity. Int J Inflam 2011: 376909. - PMC - PubMed
1. Mattu HS, Randeva HS (2013) Role of adipokines in cardiovascular disease. J Endocrinol 216: T17–36. - PubMed

Obesity, high-molecular-weight (HMW) adiponectin, and metabolic risk factors: prevalence and gender-specific associations in Estonia - PubMed (original) (raw)